| 翻訳と辞書 |
Alogliptin
Alogliptin (trade name Nesina in the US〔 and Vipidia in Europe〔(Vipidia: EPAR summary for the public ) (European Medicines Agency)〕) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class,〔 developed by Syrrx, a company which was (acquired ) by Takeda Pharmaceutical Company in 2005. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.
==Medical uses==
Alogliptin is a dipeptidyl peptidase-4 inhibitor that decreases blood sugar similar to the other.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Alogliptin」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|